1193 completed, 491 unknown, 467 recruiting, 434 terminated. 3127 Phase 2, 722 Phase 1, 80 Phase 3.
Follow Carcinoma, Non-Small-Cell Lung: new trials by email Literature Review of Carcinoma, Non-Small-Cell Lung trials Research Report on Carcinoma, Non-Small-Cell Lung
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Not yet recruiting | Xemed LLC | 10 | 2027-03-01 | 2026-09-01 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 89 | 2026-12-01 | 2026-02-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy - Non-Small Cell Carcinoma of Lung, Locally Advanced | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-15 | 2026-10-20 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-04 | 2026-10-30 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-04 | 2026-10-30 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-04 | 2026-10-30 |
| Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer TUB-040 - NSCLC, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Gilead Sciences | 80 | 2026-11-01 | 2026-09-16 |
| SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer SSGJ-706, SPGL008, Chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 220 | 2026-11-01 | 2026-10-15 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
| RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2026-11-01 | 2026-10-05 |
Showing 20 of 3127. Sign in to see all of them.
Lung Neoplasms (773) · Neoplasms (154) · Melanoma (143) · Colorectal Neoplasms (140) · Neoplasm Metastasis (140) · Adenocarcinoma of Lung (132) · Breast Neoplasms (115) · Squamous Cell Carcinoma of Head and Neck (106) · Small Cell Lung Carcinoma (101) · Carcinoma, Renal Cell (93) · Brain Neoplasms (90) · Ovarian Neoplasms (90) · Pancreatic Neoplasms (85) · Stomach Neoplasms (75)
Carcinoma, Bronchogenic (3116) · Respiratory Tract Diseases (3112) · Neoplasms by Site (3111) · Bronchial Neoplasms (3110) · Respiratory Tract Neoplasms (3110) · Thoracic Neoplasms (3106) · Lung Diseases (3101) · Neoplasms (2973) · Lung Neoplasms (2354) · Neoplasms by Histologic Type (553) · Neoplasms, Glandular and Epithelial (490) · Carcinoma (411) · Adenocarcinoma (282) · Skin and Connective Tissue Diseases (273) · Skin Diseases (271)
Carboplatin (463) · Pemetrexed (361) · Cisplatin (298) · Paclitaxel (276) · Docetaxel (266) · pembrolizumab (238) · Gemcitabine (195) · Erlotinib Hydrochloride (191) · Bevacizumab (157) · Radiotherapy (151) · Nivolumab (142) · osimertinib (109) · Drug Therapy (95) · durvalumab (95) · atezolizumab (74)
National Cancer Institute (NCI) (90) · Eli Lilly and Company (81) · Sun Yat-sen University (63) · M.D. Anderson Cancer Center (60) · Pfizer (44) · Memorial Sloan Kettering Cancer Center (40) · AstraZeneca (37) · Bristol-Myers Squibb (36) · Novartis Pharmaceuticals (35) · Hoffmann-La Roche (31) · Tianjin Medical University Cancer Institute and Hospital (29) · Alliance for Clinical Trials in Oncology (28) · Fudan University (27) · SWOG Cancer Research Network (27) · Hunan Province Tumor Hospital (26)
United States (1510) · China (757) · Spain (335) · France (309) · South Korea (280) · Italy (257) · Canada (243) · Germany (230) · United Kingdom (191) · Taiwan (183) · Australia (179) · Belgium (152) · Netherlands (142) · Poland (131) · Japan (128)
Mariano Provencio, MD (11) · Li Zhang, MD (9) · Yongchang Zhang, MD (9)
PMID 22586319, PMID 23442309, PMID 26291023, PMID 19692680, PMID 26104945, PMID 27130468, PMID 29658848, PMID 30207593, PMID 33241650, PMID 35537408, PMID 37934000, PMID 40341199, PMID 11698646, PMID 15771580, PMID 15800326, PMID 16014882, PMID 16204011, PMID 17075123, PMID 17167137, PMID 18565862, PMID 20516428, PMID 20636820, PMID 22325357, PMID 22327623, PMID 22333554, PMID 23533264, PMID 25175099, PMID 25349307, PMID 25497558, PMID 26148750, PMID 26712084, PMID 27718847, PMID 27745820, PMID 27825636, PMID 27863201, PMID 27959700, PMID 28271869, PMID 28755607, PMID 28885881, PMID 29293889, PMID 29658856, PMID 29748847, PMID 29768119, PMID 30098152, PMID 30267838, PMID 30512189, PMID 30596880, PMID 31085043, PMID 31345012, PMID 31527168
2023 (47), 2016 (28), 2017 (28), 2018 (27), 2025 (23), 2019 (22), 2014 (19), U10CA032102 (19), 2015 (16), U10CA180888 (16), U10CA031946 (15), 2008 (12), P30CA022453 (12), U10CA021115 (12), 2009 (10)